Sinopharm Announces Beijing Approval of COVID-19 Vaccine Trials

CHINA National Pharmaceutical Group (a division of Sinopharm) said its second-generation covid-19 vaccine has received Beijing's approval for clinical trials. it is reported by BLOOMBERG.

There is currently a new outbreak in China. More than 13,000 new cases of COVID-19 have been reported today. The authorities of Shanghai, which is located in the eastern part of China , have decided to close the city from March 28.

Follow the news of the companies in the TELEGRAM channel "Catalog of RBC Investments"